Clinical Neurology and Neurosurgery
Volume 112, Issue 4 , Pages 291-295 , May 2010

Adverse effects of carbamazepine, phenytoin, valproate and lamotrigine monotherapy in epileptic adult Chinese patients

Received 25 September 2008 ,Revised 18 December 2009 ,Accepted 21 December 2009.

References 

  1. Hauser AW, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota 1935–84. Epilepsia. 1993;34:453–468
  2. MacDonald BK, Cockerell OC, Sander JW, Shorvon SD. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain. 2000;123(Pt 4):665–676
  3. Burneo JG, Tellez-Zenteno J, Wiebe S. Understanding the burden of epilepsy in Latin America: a systematic review of its prevalence and incidence. Epilepsy Res. 2005;66:63–74
  4. Kale R. The treatment gap. Epilepsia. 2002;43(Suppl. 6):S31–S33
  5. Preux PM, Druet-Cabanac M. Epidemiology of epilepsy in sub-Saharan Africa. Lancet Neurol. 2005;4:21–31
  6. Sander JW, Shorvon SD. Epidemiology of the epilepsies. J. Neurol. Neurosurg. Psychiatry. 1996;61(5):433–443
  7. Scott RA, Lhatoo SD, Sander JWAS. The treatment of epilepsy in developing countries: where do we go from here?. Bull. World Health Organ. 2001;79:344–351
  8. Li SC, Schoenberg BS, Wang CC, Cheng XM, Zhou SS, Bolis C. Epidemiology of epilepsy in urban areas of the People's Republic of China. Epilepsia. 1985;26:391–394
  9. Wang W, Wu J, Wang D, Chen G, Wang T, Yuan C, et al. Epidemiological survey on epilepsy among rural populations in five provinces in China. Zhonghua Yi Xue Za Zhi. 2002;82:449–452
  10. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet. 1995;345:476–479
  11. Steiner TJ, Dellaportas CI, Findley LJ. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia. 1999;40:601–607
  12. Carpay JA, Aldenkamp AP, Donselaar CA. Complaints associated with the use of antiepileptic drugs: results from a community-based study. Seizure. 2005;14:198–206
  13. Ghaffarpour M, Hejazie SS, Harirchian MH, Pourmahmoodian H. Phenytoin, carbamazepine, sodium valproate and lamotrigine induced cutaneous reactions. Acta Med. Iran. 2005;43(1):37–42
  14. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N. Engl. J. Med. 1995;333(24):1600–1607
  15. Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology. 1997;49(2):542–546
  16. Commission on Classification . Commission on classification and terminology of the international league against epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia. 1989;30(4):389–399
  17. Bootsma HPR, Vos AM, Hulsman J, Lambrechts D, Leenen L, Majoie M, et al. Lamotrigine in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav. 2008;12:262–268
  18. Glauser TA. Behavioral and psychiatric adverse events associated with antiepileptic drugs commonly used in pediatric patients. J. Child Neurol. 2004;19(Suppl. 1):S25–S38
  19. Biton V, Mirza W, Montouris G, Vuon g A, Hammer AE, Barrett PS. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology. 2001;56:172–177
  20. Corman CL, Leung NM, Guberman AH. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can. J. Neurol. Sci. 1997;24:240–244
  21. Zampon N, Cardinal C. Open comparative long-term study of vigabatrin vs carbamazepine in newly diagnosed partial seizures in children. Arch. Neurol. 1999;56:605–607
  22. LaRoche SM, Helmers SL. The new antiepileptic drugs: clinical applications. JAMA. 2004;291(5):605–614[Review]
  23. LaRoche SM, Helmers SL. The new antiepileptic drugs: clinical applications. JAMA. 2004;291(5):615–620[Review]
  24. Matsuo F. Lamotrigine. Epilepsia. 1999;40(Suppl. 5):S30–S36
  25. Guberman AH, Besag FM, Brodie MJ, Dooley JM, Duchowny MS, Pellock JM, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia. 1999;40(7):985–991
  26. Mackay FJ, Wilton LV, Pearce GL, Freemantle SN, Mann RD. Safety of long-term lamotrigine in epilepsy. Epilepsia. 1997;38(8):881–886
  27. Thome-Souza S, Freitas A, Fiore LA, Valente KD. Lamotrigine and valproate: efficacy of co-administration in a pediatric population. Pediatr. Neurol. 2003;28(5):360–364
  28. Culy CR, Goa KL. Lamotrigine. A review of its use in childhood epilepsy. Paediatr. Drugs. 2000;2(4):299–330
  29. Dooley J, Camfield P, Gordon K, Camfield C, Wirrell E, Smith E. Lamotrigine-induced rash in children. Neurology. 1996;46(1):240–242
  30. Leong KP, Chung HH. Allergic reactions to phenytoin in a general hospital in Singapore. Asian Pac. J. Allergy Immunol. 1996;14(2):65–68
  31. Hung SI, Chung WH, Jee SH, Chen WC, Chang YT, Lee WR, et al. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics. 2006;16(4):297–306
  32. Tohen M, Castillo J, Baldessarini RJ, Zarate C, Kando JC. Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk. Am. J. Psychiatry. 1995;152:413–418
  33. Asadi-Pooya AA. Risk factors for carbamazepine-induced leukopenia in children and adolescents. J. Pediatr. Neurol. 2005;3(4):233–235
  34. May RB, Sund TR. Hematologic manifestations of long-term valproate therapy. Epilepsia. 1993;34(6):1098–1101
  35. Bohan TP, Helton E, McDonald I, Konig S, Gazitt S, Sugimoto T. Effect of l-carnitine treatment for valproate-induced hepatotoxicity. Neurology. 2001;41:1405–1409
  36. Ekaidem IS, Akpanabiatu , Uboh FE, Offiong U. Vitamin b12 supplementation: effects on some biochemical and haematological indices of rats on phenytoin administration. Biokemistri. 2006;18(1):31–37
  37. Huang YL, Hong HS, Wang ZW, Kuo TT. Fatal sodium valproate-induced hypersensitivity syndrome with lichenoid dermatitis and fulminant hepatitis. J. Am. Acad. Dermatol. 2003;49(2):316–319
  38. Roma-Giannikou E, Syriopoulou V, Kairis M, Pangali A, Sarafidou J, Constantopoulos A. In vivo effect of sodium valproate on mouse liver. Cell. Mol. Life Sci. 1999;56(3–4):363–369

PII: S0303-8467(09)00347-3

doi: 10.1016/j.clineuro.2009.12.014

Clinical Neurology and Neurosurgery
Volume 112, Issue 4 , Pages 291-295 , May 2010

Article Tools

* Image Usage & Resolution